{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:47:02Z","timestamp":1778960822091,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["GZ-2015-11442"],"award-info":[{"award-number":["GZ-2015-11442"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD) is a rare, lysosomal storage disorder caused by the absence or deficiency of the enzyme alpha-galactosidase A (\u03b1-Gal A) that leads to the abnormal accumulation of the lipid globotriaosylceramide (GB3) in a variety of cell types and tissues throughout the body. FD has an x-linked inheritance pattern. Previously thought to be only carriers, females can also experience FD symptomatology. Symptoms vary in type and severity from patient to patient and tend to increase in severity with age. FD symptoms are non-specific and may be shared with those of other diseases. Misdiagnoses and diagnostic delays are common, often resulting in progressive, irreversible tissue damage. The estimated prevalence of FD in the general population is 1:40,000 to 1:117,000 individuals. However, it is estimated that the prevalence of FD in the dialysis population is 0.12 to 0.7%. Little is known about the prevalence of FD in the broader Chronic Kidney Disease (CKD) population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an epidemiological study of the prevalence of FD in CKD patents identified from the public renal speciality practices in Queensland, Australia. A cascade approach to screening is being employed with dried blood spot testing for blood levels of alpha-galactosidase A (Alpha-Gal), with follow-up testing for patients with abnormal results by plasma levels of globotriaosylsphingosine (Lyso-GB3) for females and non-definitive cases in males. A diagnosis of FD is confirmed through genetic testing of the GLA gene in cases suspected of having FD based upon Alpha-Gal and Lyso-GB3 testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Expected outcomes of this study include more information about the prevalence of FD at all stages of CKD, including for both males and females. The study may also provide information about common characteristics of FD to assist with diagnosis and optimal management\/treatment. Screening is also available for family members of diagnosed patients, with potential for early diagnosis of FD and intervention for those individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Queensland Health Database of Research Activity (DORA, https:\/\/dora.health.qld.gov.au) <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/dora.health.qld.gov.au\/qldresearchjspui\/cris\/project\/pj09946\">pj09946<\/jats:ext-link> (Registered 3rd July 2017).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-01717-9","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T12:02:43Z","timestamp":1582372963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-2551","authenticated-orcid":false,"given":"Andrew","family":"Mallett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Kearey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy E.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"1717_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1717_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry registry. Nephrol Dial Transplant. 2010;25(3):769\u201375.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1717_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1717_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med"},{"issue":"8","key":"1717_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JTR, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry outcome survey. J Med Genet. 2009;46(8):548\u201352.","journal-title":"J Med Genet"},{"key":"1717_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1717_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1717_CR8","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI114027","volume":"83","author":"H Bernstein","year":"1989","unstructured":"Bernstein H, Bishop DF, Astrin K, Kornreich R, Eng CM, Sakuraba H, Desnick RJ. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83(4):1390\u20139.","journal-title":"J Clin Invest"},{"issue":"3954","key":"1717_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1126\/science.170.3954.180","volume":"170","author":"G Romeo","year":"1970","unstructured":"Romeo G, Migeon BR. Genetic inactivation of the \u03b1-Galactosidase locus in carriers of Fabry's disease. Science. 1970;170(3954):180\u20131.","journal-title":"Science"},{"issue":"11","key":"1717_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"key":"1717_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000060195","volume":"136","author":"K Wendrich","year":"2001","unstructured":"Wendrich K, Whybra C, Ries M, Gal A, Beck M. Neurological manifestation of Fabry disease in females. Contrib Nephrol. 2001;136:241\u20134.","journal-title":"Contrib Nephrol"},{"issue":"1","key":"1717_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"Suppl 2","key":"1717_CR13","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1016\/S0248-8663(10)70013-8","volume":"31","author":"DP Germain","year":"2010","unstructured":"Germain DP, Benistan K, Angelova L. X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. La Revue de medecine interne. 2010;31(Suppl 2):S209\u201313.","journal-title":"La Revue de medecine interne"},{"issue":"2","key":"1717_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course. Medicine. 2002;81(2):122\u201338.","journal-title":"Medicine"},{"issue":"2","key":"1717_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2008;93(2):112\u201328.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1717_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJM199102073240607","volume":"324","author":"W von Scheidt","year":"1991","unstructured":"von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, H\u00fcbner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991;324(6):395\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1717_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez ALD, Eng CM, Tanaka H, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \"renal variant\" phenotype. Kidney Int. 2003;64(3):801\u20137.","journal-title":"Kidney Int"},{"issue":"3","key":"1717_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s10157-005-0369-4","volume":"9","author":"M Ichinose","year":"2005","unstructured":"Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005;9(3):228\u201332.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1717_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20070479","volume":"406","author":"S Ishii","year":"2007","unstructured":"Ishii S, Chang H-H, Kawasaki K, Yasuda K, Wu H-L, Garman SC, Fan J-Q. Mutant alpha-galactosidase a enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J. 2007;406(2):285\u201395.","journal-title":"Biochem J"},{"key":"1717_CR20","doi-asserted-by":"crossref","unstructured":"Desnick RJ, Ioannou YA, Eng CM. Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, editors. The metabolic bases of inherited disease: McGraw-Hill; 2001. p. 3733\u201374.","DOI":"10.1006\/rwgn.2001.0443"},{"issue":"3","key":"1717_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"1","key":"1717_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJHM, Biegstraaten M, Deprez RHL, Linthorst GE, Hollak CEM. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139.","journal-title":"J Med Genet"},{"key":"1717_CR23","doi-asserted-by":"crossref","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, Schneider M, Grange DK, Nash C, Shryock H, et al. Newborn screening for Lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017.","DOI":"10.1016\/j.jpeds.2017.06.048"},{"issue":"2","key":"1717_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163(2):498\u2013503.","journal-title":"J Pediatr"},{"issue":"8","key":"1717_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58(8):548\u201352.","journal-title":"J Hum Genet"},{"issue":"10","key":"1717_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"W-L Hwu","year":"2009","unstructured":"Hwu W-L, Chien Y-H, Lee N-C, Chiang S-C, Dobrovolny R, Huang A-C, Yeh H-Y, Chao M-C, Lin S-J, Kitagawa T, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>a (IVS4+919G>a). Hum Mutat. 2009;30(10):1397\u2013405.","journal-title":"Hum Mutat"},{"issue":"8","key":"1717_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","volume":"176","author":"C Colon","year":"2017","unstructured":"Colon C, Ortolano S, Melcon-Crespo C, Alvarez JV, Lopez-Suarez OE, Couce ML, Fern\u00e1ndez-Lorenzo JR. Newborn screening for Fabry disease in the north-west of Spain. Eur J Pediatr. 2017;176(8):1075\u201381.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"1717_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000448740","volume":"134","author":"CA Silva","year":"2016","unstructured":"Silva CA, Barreto FC, Dos Reis MA, Moura Junior JA, Cruz CM. Targeted screening of Fabry disease in male hemodialysis patients in Brazil highlights importance of family screening. Nephron. 2016;134(4):221\u201330.","journal-title":"Nephron"},{"key":"1717_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000496620","volume":"1","author":"SF Yal\u0131n","year":"2019","unstructured":"Yal\u0131n SF, Eren N, Sinangil A, Yilmaz VT, Tatar E, Ucar AR, Sevinc M, Can \u00d6, Gurkan A, Arik N, et al. Fabry disease prevalence in renal replacement therapy in Turkey. Nephron. 2019;1:26.","journal-title":"Nephron"},{"key":"1717_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000495886","volume":"141","author":"S Moiseev","year":"2019","unstructured":"Moiseev S, Fomin V, Savostyanov K, Pushkov A, Moiseev A, Svistunov A, Namazova-Baranova L. The prevalence and clinical features of Fabry disease in hemodialysis patients: Russian Nationwide Fabry Dialysis screening program. Nephron. 2019;141:1\u20137.","journal-title":"Nephron"},{"issue":"2\u20133","key":"1717_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0925-4439(00)00024-7","volume":"1501","author":"R Kase","year":"2000","unstructured":"Kase R, Bierfreund U, Klein A, Kolter T, Utsumi K, Itoha K, Sandhoff K, Sakuraba H. Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta. 2000;1501(2\u20133):227\u201335.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1717_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3109\/0886022X.2012.669300","volume":"34","author":"T Nishino","year":"2012","unstructured":"Nishino T, Obata Y, Furusu A, Hirose M, Shinzato K, Hattori K, Nakamura K, Matsumoto T, Endo F, Kohno S. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients. Ren Fail. 2012;34(5):566\u201370.","journal-title":"Ren Fail"},{"issue":"9","key":"1717_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/jhg.2012.68","volume":"57","author":"K Doi","year":"2012","unstructured":"Doi K, Noiri E, Ishizu T, Negishi K, Suzuki Y, Hamasaki Y, Honda K, Fujita T, Tsukimura T, Togawa T, et al. High-throughput screening identified disease-causing mutants and functional variants of alpha-galactosidase a gene in Japanese male hemodialysis patients. J Hum Genet. 2012;57(9):575\u20139.","journal-title":"J Hum Genet"},{"issue":"4","key":"1717_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5414\/CNP64281","volume":"64","author":"M Tanaka","year":"2005","unstructured":"Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, et al. Identification of Fabry's disease by the screening of alpha-galactosidase a activity in male and female hemodialysis patients. Clin Nephrol. 2005;64(4):281\u20137.","journal-title":"Clin Nephrol"},{"issue":"6","key":"1717_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1159\/000250968","volume":"30","author":"H Fujii","year":"2009","unstructured":"Fujii H, Kono K, Goto S, Onishi T, Kawai H, Hirata K, Hattori K, Nakamura K, Endo F, Fukagawa M. Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol. 2009;30(6):527\u201335.","journal-title":"Am J Nephrol"},{"issue":"1","key":"1717_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfl528","volume":"22","author":"M Merta","year":"2007","unstructured":"Merta M, Reiterova J, Ledvinova J, Poupetov\u00e1 H, Dobrovolny R, Rysav\u00e1 R, Maixnerov\u00e1 D, Bultas J, Mot\u00e1n J, Slivkova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant. 2007;22(1):179\u201386.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1717_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5414\/CN108053","volume":"81","author":"J Herrera","year":"2014","unstructured":"Herrera J, Miranda CS. Prevalence of Fabry's disease within hemodialysis patients in Spain. Clin Nephrol. 2014;81(2):112\u201320.","journal-title":"Clin Nephrol"},{"issue":"5","key":"1717_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","volume":"15","author":"P Kotanko","year":"2004","unstructured":"Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtl\u00e4nder T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15(5):1323\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1717_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jmg.2009.072116","volume":"47","author":"GE Linthorst","year":"2010","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA, Aerts JMFG, Poorthuis BJHM, Hollak CEM. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47(4):217\u201322.","journal-title":"J Med Genet"},{"issue":"4","key":"1717_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55(4):261\u20138.","journal-title":"J Med Genet"},{"issue":"9","key":"1717_CR41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/08860220802353777","volume":"30","author":"DB Porsch","year":"2008","unstructured":"Porsch DB, Nunes AC, Milani V, Rossato LB, Mattos CB, Tsao M, Netto C, Burin M, Pereira F, Matte U, et al. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail. 2008;30(9):825\u201330.","journal-title":"Ren Fail"},{"issue":"1","key":"1717_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ndt\/gfm532","volume":"23","author":"W Terryn","year":"2008","unstructured":"Terryn W, Poppe B, Wuyts B, Claes K, Maes B, Verbeelen D, Vanholder R, De Boeck K, Lameire N, De Paepe A, et al. Two-tier approach for the detection of alpha-galactosidase a deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant. 2008;23(1):294\u2013300.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"1717_CR43","first-page":"77","volume":"43","author":"R Maslauskiene","year":"2007","unstructured":"Maslauskiene R, Bumblyte IA, Sileikiene E, Grazulis S, Laurinavicius A, Pleckaitis M, Alekniene D, Dobrovolskiene R, Vainauskas V, Juodeikiene L, et al. The prevalence of Fabry's disease among male patients on hemodialysis in Lithuania (a screening study). Medicina (Kaunas, Lithuania). 2007;43(Suppl 1):77\u201380.","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"6","key":"1717_CR44","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1159\/000452605","volume":"41","author":"K Turkmen","year":"2016","unstructured":"Turkmen K, Guclu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, Sengul E, Ozkan O, Emre H, Turgut F, et al. The prevalence of Fabry disease in patients with chronic kidney disease in Turkey: the TURKFAB study. Kidney Blood Press Res. 2016;41(6):1016\u201324.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"1717_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/0886022X.2016.1254656","volume":"39","author":"Y Yeni\u00e7erio\u011flu","year":"2017","unstructured":"Yeni\u00e7erio\u011flu Y, Akdam H, Dursun B, Alp A, Sa\u011flam Eyiler F, Ak\u0131n D, G\u00fcn Y, H\u00fcddam B, Batmazo\u011flu M, Gibyeli Genek D, et al. Screening Fabry's disease in chronic kidney disease patients not on dialysis: a multicenter study. Ren Fail. 2017;39(1):104\u201311.","journal-title":"Ren Fail"},{"issue":"10","key":"1717_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","volume":"68","author":"V Favalli","year":"2016","unstructured":"Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, et al. Genetic screening of Anderson-Fabry disease in Probands referred from multispecialty clinics. J Am Coll Cardiol. 2016;68(10):1037\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"1717_CR47","volume-title":"Interim analysis of Fabry testing in Western Australia renal dialysis patients: the FoRWARD study","author":"S Akhter","year":"2017","unstructured":"Akhter S, Alexander S, Goldblatt J, Stark S, Crawford D, Thomas M. Interim analysis of Fabry testing in Western Australia renal dialysis patients: the FoRWARD study. Darwin: ANZSN; 2017."},{"issue":"5","key":"1717_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64(5):550\u20135.","journal-title":"Pediatr Res"},{"issue":"2","key":"1717_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1717_CR50","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4238\/2013.January.24.5","volume":"12","author":"AM Martins","year":"2013","unstructured":"Martins AM, Kyosen SO, Garrote J, Marques FM, Guilhem JG, Macedo E, Sobral Neto J, Ura S. Demographic characterization of Brazilian patients enrolled in the Fabry registry. Genet Mol Res. 2013;12(1):136\u201342.","journal-title":"Genet Mol Res"},{"issue":"4","key":"1717_CR51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338\u201346.","journal-title":"Ann Intern Med"},{"key":"1717_CR52","unstructured":"Stark S, Fong B, Fletcher J, Fietz M. Screening For Fabry Disease Using Dried Blood Spots. In: 38th Human Genetics Society of Australasia Annual Scientific Meeting. Adelaide; 2014."},{"issue":"1\u20132","key":"1717_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353(1\u20132):201\u20133.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1717_CR54","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","volume":"24","author":"B Oqvist","year":"2009","unstructured":"Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant. 2009;24(6):1736\u201343.","journal-title":"Nephrol Dial Transplant"},{"issue":"1\u20132","key":"1717_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ymgme.2017.08.004","volume":"122","author":"A Talbot","year":"2017","unstructured":"Talbot A, Nicholls K, Fletcher JM, Fuller M. A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease. Mol Genet Metab. 2017;122(1\u20132):121\u20135.","journal-title":"Mol Genet Metab"},{"key":"1717_CR56","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"1717_CR57","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","volume":"126","author":"DP Germain","year":"2019","unstructured":"Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224\u201335.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1717_CR58","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","volume":"126","author":"M Spada","year":"2019","unstructured":"Spada M, Baron R, Elliott PM, Falissard B, Hilz MJ, Monserrat L, T\u00f8ndel C, Tylki-Szyma\u0144ska A, Wanner C, Germain DP. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):212\u201323.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1717_CR59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ncpneph0100","volume":"2","author":"M Banikazemi","year":"2006","unstructured":"Banikazemi M, Desnick RJ. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis? Nat Clin Pract Nephrol. 2006;2(2):72\u20133.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"21","key":"1717_CR60","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, Sabnis SG, Moore DF, Weibel T. Enzyme replacement therapy in Fabry disease: a randomised control trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"6","key":"1717_CR61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, et al. Treatment of Fabry's disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"1717_CR62","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Mar\u00f3di L, Mignani R, Vujkovac B, Beitner-Johnson D, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1717_CR63","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B, Presnyak V, Frassetto A, Milton J, Salerno T, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human Primates. Am J Hum Genet. 2019;104(4):625\u201337.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1717_CR64","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/j.ymgme.2018.12.248","volume":"126","author":"JA Medin","year":"2019","unstructured":"Medin JA, Khan A, Huang J, Barber D, Anthony Rupar C, Auray-Blais C, Fraser G, Fowler DH, Keating A, West ML, et al. FACTs Fabry gene therapy clinical trial: Two-year data. Mol Genet Metab. 2019;126(2):S99.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1717_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1717_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-017-0607-5","volume":"18","author":"SK Venuthurupalli","year":"2017","unstructured":"Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia. BMC Nephrol. 2017;18:1\u201310.","journal-title":"BMC Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-01717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T02:32:29Z","timestamp":1613874749000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1717"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01717-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The aCQuiRE Study received multi-site ethical approval from the Royal Brisbane and Women\u2019s Hospital Human Research Ethics Committee (Approval number: HREC\/7\/QRBW\/91) and subsequent governance approval at all study sites. Governance and ethical processes included approval of this protocol. All patients provide informed, written consent prior to participation in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT has previously received fees for lectures, advisory boards and conference attendance from Sanofi-Genzyme. CD is a member of the Sanofi Genzyme Educational Advisory Board and has previously received sponsorship to attend conferences. SS has received fees from Sanofi-Genzyme for Advisory Board participation. AM is a member of the BMC Nephrology Editorial Board (Associate Editor) and has had no role in the peer review or handling of this manuscript by that journal. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}